Lincoln Pharmaceuticals (NSE:LINCOLN) Institutional Ownership: 1.02% (As of Aug. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:LINCOLN Lincoln Pharmaceuticals Ltd NSE:LINCOLN
84 GF Score
Price ₹619.10
GF Value ₹730.43
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Lincoln Pharmaceuticals Institutional Ownership?

Lincoln Pharmaceuticals NSE:LINCOLN -0.68% 84 Institutional Ownership is 1.02% as of Aug. 19, 2026. GuruFocus rates NSE:LINCOLN with a GF Score™ of 84/100 and a GF Value™ of ₹730.43 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Lincoln Pharmaceuticals's institutional ownership is 1.02%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Lincoln Pharmaceuticals's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Lincoln Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 0.00%.

Lincoln Pharmaceuticals Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Lincoln Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lincoln Pharmaceuticals Institutional Ownership Chart

Lincoln Pharmaceuticals Historical Data

The historical data trend for Lincoln Pharmaceuticals can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 1.21 1.21 1.17 1.16 1.46 1.46 1.49 1.51 1.00 1.02
NSE:LINCOLN
84GF Score
Lincoln Pharmaceuticals Ltd NSE:LINCOLN
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lincoln Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 1.02% mean?
Lincoln Pharmaceuticals (NSE:LINCOLN) has a Institutional Ownership of 1.02% as of Aug. 19, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Lincoln Pharmaceuticals and its competitors.
Is Lincoln Pharmaceuticals' Institutional Ownership too high?
Lincoln Pharmaceuticals' current Institutional Ownership is 1.02%. Overall, Lincoln Pharmaceuticals has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lincoln Pharmaceuticals' Institutional Ownership compare to ZTS?
Lincoln Pharmaceuticals' Institutional Ownership of 1.02% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Lincoln Pharmaceuticals and its competitors. Lincoln Pharmaceuticals's current Institutional Ownership is 1.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lincoln Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Lincoln Pharmaceuticals (NSE:LINCOLN) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹730.43, compared to a current price of ₹619.10 — trading 15.2% below its estimated fair value. The current Institutional Ownership is 1.02%. Lincoln Pharmaceuticals' overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Lincoln Pharmaceuticals (NSE:LINCOLN), the current Institutional Ownership is 1.02% as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lincoln Pharmaceuticals (NSE:LINCOLN) Overvalued in 2026?

Based on GuruFocus' analysis, Lincoln Pharmaceuticals stock appears to be undervalued. The current stock price of ₹619.10 is trading 15.2% below its estimated GF Value™ of ₹730.43. GuruFocus considers Lincoln Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for NSE:LINCOLN:

  • Institutional Ownership: 1.02%
  • GF Value™: ₹730.43 vs. price of ₹619.10 (15.2% below fair value)
  • GF Score™: 84/100 with 2 warning signs

No single metric tells the full story. See the NSE:LINCOLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lincoln Pharmaceuticals Business Description

Other Exchanges 531633:India
Address Science City Road, Lincoln House, Behind Satyam Complex, Sola, Ahmedabad, GJ, IND, 380060
Lincoln Pharmaceuticals Ltd is an India-based company engaged in the business of manufacturing and trading of pharmaceutical products. It offers products in the fields of cardiac, diabetic, anti-malarial, anti-biotic, anti-fungal, cephalosporin, analgesics, anesthetics, anti-pyretic, GIT products, vitamin-minerals, and iron preparations. Some of the key brands through which the company markets its products are; Rhino, Binafin, Kezolin, Hepalin, Progut, and Vomistat among others. Geographically, it carries out sales in India and outside India; generating key revenue from outside India.
84GF Score

Get the complete analysis for NSE:LINCOLN

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹619.10
Price
₹730.43
GF Value